Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton’s tyrosine kinase, in Phase I clinical trials in healthy volunteers. Science ShareTwitterFacebookXingLinkedin You May Also Like Science 25. Mai 2023 CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes Science 25. Mai 2023 Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies. Science 25. Mai 2023 (Bersacapavir) In Participants With Moderate Hepatic Impairment.